Document is current

Article History

Received: 16 August 2024

Revised: 22 November 2024

Accepted: 6 December 2024

First Online: 4 February 2025

Competing interests

: The authors have no competing interests if not stated below. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Amandeep Salhotra: Received funding from Orca Bio, Bristol Myers Squibb, Rigel Pharmaceuticals. Serves on advisory board for Incyte Corporation and speaker panel for Sanofi. Haris Ali: Serves on speaker panel for Incyte Corporation.

: This study was approved by our Institutional Review Board (IRB) under registration number #22401 and met the criteria for exemption for ethics approval and consent to participate due to the retrospective nature of this study under Code of Federal Regulations 45CFR46.104 (d). Exempt Category 4 states “secondary research for which consent is not required: secondary use of identifiable private information or identifiable biospecimens, if at least the follow criteria is met: (iii) The research involves only information collection and analysis involving the investigator’s use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of “health care operations” or “research” as those are defined as 45 CFR 164.501 or for “public health activities and purposes” as described under 45 CFR 164.512 (b).